Edity is an Israel-based company developing a novel delivery platform that uses immune cells to transfer therapeutic proteins to the target cells of patients. Their technology allows for precise modulation of intracellular pathways of disease using a range of proteins including gene editors, immune sensors, enzymes and intrabodies.